Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

Autor: Koos van Dam, Adriaan Volkers, Luuk Wieske, Eileen Stalman, Laura Kummer, Zoe van kempen, Joep Killestein, Sander Tas, Laura Boekel, Gertjan Wolbink, Anneke van der Kooi, Joost Raaphorst, Bart Takkenberg, Geert D'Haens, Phyllis Spuls, Marcel Bekkenk, Annelie Musters, Nicoline Post, Angela Bosma, Marc Hilhorst, Yosta Vegting, Frederike Bemelman, Alexandre Voskuyl, Bo Broens, Agner Parra Sanchez, Cecile van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horvath, Jan Verschuuren, Annabel Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Renee Allaart, Onno Teng, Pieter van Paassen, Matthias Busch, Papay Jallah, Esther Brusse, Pieter van Doorn, Adaja Baars, DirkJan Hijnen, Corine Schreurs, Ludo van der Pol, Stephan Goedee, Maurice Steenhuis, Sofie Keijzer, Jim Keijser, Olvi Cristianawati, Anja ten Brinke, Niels Verstegen, Marieke van Ham, Theo Rispens, Taco Kuijpers, Mark Lowenberg, Filip Eftimov
Přispěvatelé: Translational Immunology Groningen (TRIGR)
Rok vydání: 2023
Předmět:
Zdroj: BMC Infectious Diseases, 23:332. BMC
ISSN: 1471-2334
DOI: 10.21203/rs.3.rs-2272601/v1
Popis: Background: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-term humoral immune responses against SARS-CoV-2 and increased disease activity after a primary SARS-CoV-2 infection in unvaccinated IMID patients on ISPs. Methods: IMID patients on active treatment with ISPs and controls (i.e. IMID patients not on ISP and healthy controls) with a confirmed SARS-CoV-2 infection before first vaccination were included from an ongoing prospective cohort study (T2B! study). Clinical data on infections and increased disease activity were registered using electronic surveys and health records. A serum sample was collected before first vaccination to measure SARS-CoV-2 anti-receptor-binding domain (RBD) antibodies. Results: In total, 193 IMID patients on ISP and 113 controls were included. Serum samples from 185 participants were available, with a median time of 173 days between infection and sample collection. The rate of seropositive IMID patients on ISPs was 78% compared to 100% in controls (pConclusion: IMID patients using ISPs showed reduced long-term humoral immune responses after primary SARS-CoV-2 infection, which was mainly attributed to treatment with anti-CD20 and anti-TNF agents. Increased disease activity after SARS-CoV-2 infection was reported commonly, but was mostly mild. Trial registration NL74974.018.20, Trial ID: NL8900. Registered on 9 September 2020.
Databáze: OpenAIRE
Externí odkaz: